These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29023843)

  • 61. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU
    Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A categorical structure-activity relationship analysis of GPR119 ligands.
    Kumar P; Carrasquer CA; Carter A; Song ZH; Cunningham AR
    SAR QSAR Environ Res; 2014; 25(11):891-903. PubMed ID: 25401513
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice.
    Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y
    Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic application of GPR119 ligands in metabolic disorders.
    Yang JW; Kim HS; Choi YW; Kim YM; Kang KW
    Diabetes Obes Metab; 2018 Feb; 20(2):257-269. PubMed ID: 28722242
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists.
    Fang Y; Yang Z; Gundeti S; Lee J; Park H
    Bioorg Med Chem; 2017 Jan; 25(1):254-260. PubMed ID: 27825553
    [TBL] [Abstract][Full Text] [Related]  

  • 66. GPR119 as a fat sensor.
    Hansen HS; Rosenkilde MM; Holst JJ; Schwartz TW
    Trends Pharmacol Sci; 2012 Jul; 33(7):374-81. PubMed ID: 22560300
    [TBL] [Abstract][Full Text] [Related]  

  • 67. GPR119: a promising target for nonalcoholic fatty liver disease.
    Yang JW; Kim HS; Im JH; Kim JW; Jun DW; Lim SC; Lee K; Choi JM; Kim SK; Kang KW
    FASEB J; 2016 Jan; 30(1):324-35. PubMed ID: 26399788
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor.
    Mascitti V; Stevens BD; Choi C; McClure KF; Guimarães CR; Farley KA; Munchhof MJ; Robinson RP; Futatsugi K; Lavergne SY; Lefker BA; Cornelius P; Bonin PD; Kalgutkar AS; Sharma R; Chen Y
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1306-9. PubMed ID: 21310611
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.
    Zhu J; Ye Y; Ning M; Mándi A; Feng Y; Zou Q; Kurtán T; Leng Y; Shen J
    ChemMedChem; 2013 Jul; 8(7):1210-23. PubMed ID: 23757200
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119.
    Xu P; Huang S; Guo S; Yun Y; Cheng X; He X; Cai P; Lan Y; Zhou H; Jiang H; Jiang Y; Xie X; Xu HE
    Nat Struct Mol Biol; 2022 Sep; 29(9):863-870. PubMed ID: 35970999
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity.
    Chen J; Sang Z; Li L; He L; Ma L
    Mol Divers; 2017 Aug; 21(3):637-654. PubMed ID: 28656523
    [TBL] [Abstract][Full Text] [Related]  

  • 72. GPR119 regulates genetic markers of fatty acid oxidation in cultured skeletal muscle myotubes.
    Cornall LM; Mathai ML; Hryciw DH; Simcocks AC; O'Brien PE; Wentworth JM; McAinch AJ
    Mol Cell Endocrinol; 2013 Jan; 365(1):108-18. PubMed ID: 23069642
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The first pharmacophore model for potent G protein-coupled receptor 119 agonist.
    Zhu X; Huang D; Lan X; Tang C; Zhu Y; Han J; Huang W; Qian H
    Eur J Med Chem; 2011 Jul; 46(7):2901-7. PubMed ID: 21524831
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists.
    Sato K; Sugimoto H; Rikimaru K; Imoto H; Kamaura M; Negoro N; Tsujihata Y; Miyashita H; Odani T; Murata T
    Bioorg Med Chem; 2014 Mar; 22(5):1649-66. PubMed ID: 24508142
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
    Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
    J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
    [TBL] [Abstract][Full Text] [Related]  

  • 76. G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
    Ritter K; Buning C; Halland N; Pöverlein C; Schwink L
    J Med Chem; 2016 Apr; 59(8):3579-92. PubMed ID: 26512410
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
    Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions.
    Lu SY; Jiang YJ; Lv J; Wu TX; Yu QS; Zhu WL
    J Mol Graph Model; 2010 Jun; 28(8):766-74. PubMed ID: 20227312
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
    Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
    [TBL] [Abstract][Full Text] [Related]  

  • 80. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.
    Fyfe MC; McCormack JG; Overton HA; Procter MJ; Reynet C
    Expert Opin Drug Discov; 2008 Apr; 3(4):403-13. PubMed ID: 23489096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.